Home > Haematology > ASH 2021 > Chronic Leukaemia > SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL

SEQUOIA: Zanubrutinib meets primary endpoint for treatment-naïve CLL/SLL

Presented By
Prof. Constantine Tam, Peter MacCallum Cancer Centre, Australia

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
ASH 2021
Trial
Phase 3, SEQUOIA
Zanubrutinib outperformed bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). The effect was consistent across high-risk subgroups, such as patients with unmutated IGHV or del(11q). The results of this phase 3 trial showed that zanubrutinib, a chemotherapy-free therapy, is an effective frontline therapy for patients with CLL/SLL [1]. Zanubrutinub is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor that has demonstrated favourable efficacy and safety in patients with Waldenström macroglobulinaemia and relapsed refractory CLL/SLL [2,3]. Cohort 1 of the current open-label, phase 3 SEQUOIA trial (NCT03336333) randomised 479 patients with treatment-naïve CLL/SLL without del(17p) who were unfit for intensive chemotherapy 1:1 to zanubrutinib (160 mg, twice daily) or a re...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on